Prescribing guide
Papzimeos (zopapogene imadenovec-drba)Dosing schedule, debulking timing, frozen storage and thaw handling, and prior authorization criteria for recurrent respiratory papillomatosisFor prescribers and their offices treating recurrent respiratory papillomatosis: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No boxed warning or contraindications in the label and no REMS requirement in the approval letter; surgical debulking of visible papilloma before dose 1; a site of care with a freezer at -60°C or colder and a 37°C water or dry bead bath; Papzimeos SUPPORT Enrollment Form; insurer approval before the order is fulfilled; order at least 2 weeks before the planned administration.
Example PA threshold
FEP 5.01.081 example: age 18 or older, pathology-confirmed papilloma, laryngotracheal papillomas, 3 or more debulking procedures in the last 12 months, prescriber agrees to monitor for injection-site reactions and thrombotic events; 4 vials per lifetime, no renewal.
Monitoring
At least 30 minutes of observation for local site reactions after the initial treatment; signs and symptoms of thrombotic events, with no time window stated; visible papilloma before doses 3 and 4; no laboratory monitoring specified.
Support line
Papzimeos SUPPORT, 1-866-827-8180, Monday to Friday, 8am to 8pm ET, fax 1-833-813-8580; benefits investigation, copay program as little as $0 for commercially insured patients, specialty pharmacy ordering and delivery to the site of care.
Give your patient their plan
A one-page handout for starting Papzimeos, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/papzimeosBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Confirm the indication | Treatment of adults with recurrent respiratory papillomatosis. Safety and effectiveness in pediatric patients have not been established. | FDA label |
| Approval type | Precigen filed under the accelerated approval pathway and said the FDA granted full approval, which does not require a confirmatory clinical trial. | Precigen announcement |
| Debulk first | Perform surgical debulking of visible papilloma before the initial administration to establish minimal residual disease. The label sets no interval between the surgery and dose 1. | FDA label |
| Enroll with Papzimeos SUPPORT | Access starts with the Papzimeos SUPPORT Enrollment Form, online or by fax to (833) 813-8580, with the patient's clinical history, insurance coverage and site of care. Precigen's page says Biologics contacts the patient for a signature. | Precigen prescriber site |
| Choose the fulfillment route | Buy and bill through the specialty distributor, Cencora, or specialty pharmacy fulfillment, in which Precigen's exclusive specialty pharmacy places the order with Cencora and coordinates delivery to the site of care. | Precigen ordering guide |
| Order timing | Place orders at least 2 weeks before the planned administration. Orders are fulfilled once the insurer approves the prescription; delivery is expected in 2 to 3 business days, scheduled Tuesday through Friday, with an extra day for specialty pharmacy and first-time buy-and-bill orders. | Precigen ordering guide |
| What the order asks for | Account number, vial quantity, PO number, confirmation of a -60°C (-76°F) or colder freezer, verification of insurer approval, insurer name, confirmed treatment date, prescribing physician, dose number, and delivery date, time and contacts. | Precigen ordering guide |
| Site of care equipment | Freezer at -60°C (-76°F) or colder, water bath or dry bead bath at 37°C (98.6°F), 3mL sterile syringe, 18G to 22G needle without a filter for withdrawal, 23G to 25G needle (1/2 to 5/8 inch) for injection, 70% isopropyl alcohol pads. | FDA label |
| Receiving the shipment | Shipped frozen on dry ice in an insulated box with 2 temperature monitors, up to 4 vials per box, each in its own carton. Verify temperature, then move cartons to the ultra-cold freezer immediately. For damaged product the guide gives Precigen at (855) 743-6777. | Precigen ordering guide |
| Counsel before dose 1 | Injection-site reaction signs and when to seek care; thrombotic event signs (shortness of breath, chest pain, leg swelling, persistent abdominal pain, severe or persistent headaches, blurred vision); dressing disposal and hand hygiene for 1 to 2 weeks after each injection. | FDA label |
Prior authorization criteria and what to document
One public policy as the example: FEP Blue (Blue Cross and Blue Shield Federal Employee Program), effective July 1, 2026. Approval one approval for 4 vials, the 4 injections, per lifetime, with no renewal. The policy does not state a length of time for the approval.. FEP policy 5.01.081 was first written on October 24, 2025 and last reviewed on June 11, 2026. It cites the August 2025 package insert, the same label used on this page. Its surgery count matches who the trial enrolled, while the label covers adults with the condition and names no number of surgeries. Other plans set their own rules, which can differ from this example.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Age | 18 years of age or older | Date of birth on the request | FEP Blue policy |
| Diagnosis | Recurrent respiratory papillomatosis with a histological diagnosis of papilloma confirmed by pathology report | Pathology report with date | FEP Blue policy |
| Disease site | Presence of laryngotracheal papillomas | Laryngoscopy or operative note describing the papillomas | FEP Blue policy |
| Surgical burden | A history of 3 or more debulking procedures to remove laryngotracheal papillomas in the last 12 months | Dated operative notes for the prior 12 months; the label indication names no surgery count | FEP Blue policy |
| Monitoring attestation | Prescriber agrees to monitor for injection-site reactions and thrombotic events | Statement on the request or in the plan of care | FEP Blue policy |
| Quantity | 4 vials; only one prior approval for four injections per lifetime; no renewal | Request all 4 doses in the one approval, with planned dates | FEP Blue policy |
| Trial diagnosis standard | PRGN-2012-201 required a pathology report from a CLIA-certified or comparable laboratory and laryngotracheal papillomas with or without pulmonary RRP | A trial inclusion criterion. FEP asks for the pathology report and laryngotracheal papillomas without the CLIA laboratory wording, and the label indication has neither | ClinicalTrials.gov |
Papzimeos dosing and titration
| When | Label | Source |
|---|---|---|
| Before dose 1 | Debulk visible papilloma to minimal residual disease; the label gives no interval. | FDA label |
| Initial, then weeks 2, 6 and 12 | 5×10^11 PU (1mL) subcutaneously per administration, 4 administrations over a 12-week interval. The second administration should occur no less than 11 days after the initial one. Study days were 1, 15, 43 and 85. | FDA label |
| Before doses 3 and 4 | Remove visible papilloma, if present, to maintain minimal residual disease during treatment. | FDA label |
| Thaw | Take the vial out of the pouch and thaw at once, upright, in a 37°C (98.6°F) water bath or dry bead bath until no ice crystals are visible; exposure to the bath 5 minutes or less. Thaw rapidly and prepare for immediate administration. | FDA label |
| Prepare | Wipe the vial and stopper with 70% isopropyl alcohol, swirl gently, do not shake. Slightly opalescent to opalescent, colorless, free of visible particulates; do not use if particulates or discoloration. Withdraw 1mL with a 3mL syringe and 18G to 22G needle, no filter needle; change to a 23G to 25G needle. | FDA label |
| Time limits after thaw | No more than 60 minutes at room temperature. Do not put thawed vials or filled syringes in a refrigerator, freezer or on dry ice. Protect from light. | FDA label |
| Site and technique | Lateral upper arm or thigh; avoid edema, potential infection, wounds, scars or a recent subcutaneous injection site. Alcohol swab, at least 30 seconds to dry, needle at an angle for subcutaneous delivery, swab again, do not massage. | FDA label |
| After the injection | Dressings and other potentially contaminated materials from the site go in a sealable bag into regular trash, for 1 to 2 weeks after injection; hand hygiene on contact with patient body waste; no direct contact with the site and dressings for about 24 hours. | FDA label |
| Spills and waste | Treat spills with a virucidal agent, such as sodium hypochlorite with 0.5% active chlorine or 6% hydrogen peroxide, for 15 minutes. Used needle and empty vial go in a biohazard container; unused product and waste follow facility biohazard procedure. Universal biosafety precautions apply. | FDA label |
| Missed dose | The label has no missed-dose or delayed-dose instruction beyond the 11-day minimum before dose 2. | FDA label |
| Supply | One single-dose cyclic olefin polymer vial per carton, 5×10^11 PU in 1mL extractable, sealed in a pouch; carton NDC 84768-511-01, vial NDC 84768-511-99, pouch NDC 84768-511-00. No preservatives. | FDA label |
| Storage | Shipped and stored frozen at -60°C (-76°F) or colder until ready to thaw and administer. Do not refreeze or refrigerate once removed from the pouch. | FDA label |
| Dating period | 24 months from the date of manufacture when stored at -60°C or colder. | FDA approval letter |
Monitoring the Papzimeos label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| After the initial treatment | Local injection-site reactions | Monitor for at least 30 minutes and manage accordingly; the label's 30-minute instruction names the initial treatment only | FDA label |
| After any dose | Signs and symptoms of thrombotic events | Treat according to clinical practice; the label cites the potential of adenoviral vectors to induce prothrombotic antibodies and states no monitoring window or laboratory test | FDA label |
| Before doses 3 and 4 | Visible papilloma | Remove if present | FDA label |
| Adverse reactions in PRGN-2012-201 | Injection site reaction 97%, fatigue 74%, chills 66%, pyrexia 63%, myalgia 29%, nausea 26%, headache 11%, tachycardia 8%, diarrhea 5%, vomiting 5%, hyperhidrosis 5% (N=38) | All grade 1 to 2. Under 5%, each 3%: vision blurred, injection site bruising, dizziness, dyspnea, pruritus | FDA label |
| Laboratory | None specified | The label lists no baseline or on-treatment laboratory tests | FDA label |
| 12 and 24 months after treatment | Need for surgical intervention | Complete response, no surgery in 12 months, in 18 of 35 (51%, 95% CI 34 to 69%); 15 of the 18 continued at 24 months (43%, 95% CI 26 to 61%) | FDA label |
| Immune response | HPV 6 and HPV 11 specific T cells at completion of treatment in 28 patients | Mean fold-change from baseline 164.9 in responders against 5.1 in non-responders; a pharmacodynamic finding, not a test to order | FDA label |
| Adverse event reporting | Precigen at 855-743-6777 or FDA MedWatch | The approval letter requires Precigen to file thrombotic event reports as 15-day expedited reports for 3 years from licensure | FDA approval letter |
| Postmarketing commitments | Viral shedding study in adults; single-arm study in pediatric patients; final PRGN-2012-201 report | Final reports due December 31, 2026, December 31, 2028 and December 31, 2026 | FDA approval letter |
Papzimeos drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Drug interactions | The label has no drug interactions section and lists none | FDA label |
| Immunosuppression | The label has no statement on immunosuppressed patients or concurrent immunosuppressants | FDA label |
| Trial exclusions, not label rules | PRGN-2012-201 excluded systemic corticosteroids above 10mg daily prednisone equivalent or other immunosuppressive medications within 14 days of study drug, and required a 30-day washout after systemic bevacizumab | ClinicalTrials.gov |
| Vector shedding | No biodistribution or vector shedding studies have been conducted; the label's dressing and hand hygiene precautions run 1 to 2 weeks after injection | FDA label |
| Pregnancy and lactation | No data in pregnant women and no animal reproductive studies; one trial patient became pregnant 6 months after treatment and delivered at 40 weeks without reported complications. No information on presence in human milk | FDA label |
| Age 65 and older | 9 patients (24%) were 65 or older and 1 (3%) was 75 or older; too few to determine whether response differs | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe example FEP Blue policy asks for a pathology report and papillomas in the larynx or windpipe. It also asks for 3 or more debulking surgeries in the last 12 months, a number the label does not require. Precigen says Papzimeos SUPPORT gives information on prior authorization and helps with appeals when it is the specialty pharmacy.
- A request for a second courseThe example FEP Blue policy allows only one approval, for 4 injections per lifetime, and has no renewal. The label describes a course of 4 doses and no retreatment course after it.
- The clinic cannot store itThe label requires storage in a freezer at minus 76 degrees Fahrenheit or colder until the vial is thawed. Precigen says your ENT may need to work with other specialists and facilities that can store and give Papzimeos. Precigen's patient site has a site locator for places that give it.
- The vial was not ordered or approved in timePrecigen's ordering guide asks for orders at least 2 weeks before the planned injection. It says orders are filled once the insurer has approved the prescription, so the approval comes first.
- A cost question on Medicare, Medicaid or other government insurancePrecigen's copay program is only for people with commercial insurance. Its terms exclude Medicare, Medicaid, VA, Department of Defense and TRICARE coverage. Precigen's patient site says Papzimeos is covered by Medicare and Medicaid, and Papzimeos SUPPORT can explain your costs.
- The patient is under 18The label covers adults only, and the example FEP Blue policy requires age 18 or older. Precigen has committed to the FDA to study Papzimeos in children, with a final report due by December 31, 2028.
Papzimeos SUPPORT
- Help with the insurance process and the information your health plan may need
- A copay program that may bring out-of-pocket cost to as little as $0 for eligible people with commercial insurance, with no income requirements
- A representative who tracks your enrollment, with automatic review for the copay program if your copay is high
- Precigen says Papzimeos is covered by Medicare and Medicaid, and that coverage is growing
- The copay program terms exclude Medicare, Medicaid, VA, Department of Defense and TRICARE coverage, and anyone getting help from another program or foundation Precigen prescriber site
- The copay program helps only with the cost of Papzimeos and giving it, up to a program maximum that the page does not state Precigen prescriber site
- Precigen's exclusive specialty pharmacy runs the program and can order the vial and arrange delivery to the site of care Precigen ordering guide
- No free drug or bridge program is described on the pages we read on November 11, 2026
Questions prescribers' offices ask about Papzimeos
What is the Papzimeos dosing schedule?
Four subcutaneous injections of 5×10^11 particle units (1mL) over 12 weeks, per the August 2025 label: initial, then 2, 6 and 12 weeks after the initial administration. The second dose should be no less than 11 days after the first; the pivotal study dosed on days 1, 15, 43 and 85, and the label describes no retreatment course.
When is debulking done relative to Papzimeos doses?
Before dose 1, and again before doses 3 and 4 if visible papilloma is present, per the August 2025 label, which sets no interval in days. In PRGN-2012-201 the protocol-mandated debulking was on day 1, and physicians could remove visible papillomas during the treatment interval.
How is Papzimeos stored and thawed?
Stored at -60°C (-76°F) or colder and thawed for no more than 5 minutes in a 37°C water bath or dry bead bath, per the August 2025 label. Once thawed it is not held at room temperature for more than 60 minutes and never returned to a refrigerator, freezer or dry ice; do not shake, and protect from light.
Does Papzimeos have a REMS, boxed warning or contraindications?
The August 2025 label has no boxed warning and lists no contraindications, and the August 14, 2025 approval letter sets no REMS requirement. The 2 warnings are injection-site reactions, with at least 30 minutes of monitoring after the initial treatment, and thrombotic events, which may follow adenoviral vector-based therapies.
What do insurers ask for to approve Papzimeos?
FEP policy 5.01.081, effective July 1, 2026, asks for age 18 or older, RRP with a pathology-confirmed histological diagnosis, laryngotracheal papillomas, 3 or more debulking procedures in the last 12 months and a prescriber who agrees to monitor for injection-site reactions and thrombotic events. It allows 1 approval for 4 vials per lifetime with no renewal; the label indication itself names no surgery count.
Free email alert
Get an email when the Papzimeos label changes
One email the day the FDA revises the Papzimeos prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Papzimeos only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- Package Insert - PAPZIMEOS (zopapogene imadenovec-drba) suspension for subcutaneous injection, Revised 08/2025, FDA, Center for Biologics Evaluation and Research, 2025-08-12.
- PAPZIMEOS, FDA, Center for Biologics Evaluation and Research, 2026-03-02.
- August 14, 2025 Approval Letter - PAPZIMEOS, FDA, Center for Biologics Evaluation and Research, 2025-08-14.
- February 25, 2026 Approval Letter - PAPZIMEOS, FDA, Center for Biologics Evaluation and Research, 2026-02-25.
- FDA Approves First Immunotherapy for Recurrent Respiratory Papillomatosis, FDA, 2025-08-14.
- Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis, Precigen, 2025-08-15.
- Access & Support | PAPZIMEOS® (zopapogene imadenovec-drba), Precigen, 2026-11-11.
- Why PAPZIMEOS? | Starting PAPZIMEOS® (zopapogene imadenovec-drba), Precigen, 2026-11-11.
- PAPZIMEOS (zopapogene imadenovec-drba) Navigating Access, Precigen, 2026-11-11.
- Distribution and Product Ordering Guide: Information to Help You With Ordering and Receiving PAPZIMEOS, Precigen, 2025-09.
- 5.01.081 Papzimeos, Blue Cross Blue Shield Association, Federal Employee Program, 2026-07-01.
- Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis, NCT04724980, ClinicalTrials.gov, record verified June 2025, 2026-11-11.
A reference drawn from the August 12, 2025 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 11, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.